Pathology: mHNSCC - L2 - all population;
| mHNSCC - L2 - all population | |||||
| EAGLE (D vs ICC), 2019 | EAGLE (DT vs ICC), 2019 | CheckMate 141, 2016 | KEYNOTE-040 (all population), 2018 | ||
| durvalumab alone | 1 | T1 | |||
| durvalumab plus tremelimumab | 1 | T1 | |||
| pembrolizumab alone | 1 | T1 | |||
| nivolumab alone | 1 | T1 | |||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 |